Jenniffier Eady
Family Medicine · Southlake, TXNPI 1508093733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $752 and has fallen 97.0% since, to $23 in 2025.
Across 106 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$286
- Boehringer Ingelheim$283
- Lilly USA, LLC$145
- Novo Nordisk$128
- Biohaven Pharmaceuticals, Inc.$121
- GSK$114
- plus $840 from 25 others
What the payments were for
- Food & beverage$1,917100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $286 |
| Boehringer Ingelheim | 16 | $283 |
| Lilly USA, LLC | 9 | $145 |
| Novo Nordisk | 9 | $128 |
| Biohaven Pharmaceuticals, Inc. | 3 | $121 |
| GSK | 6 | $114 |
| Cleerly, Inc. | 2 | $100 |
| Supernus Pharmaceuticals, Inc. | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Astellas Pharma US Inc | 3 | $53 |
| Exact Sciences | 2 | $49 |
| Merck | 3 | $46 |
| Genentech USA, Inc. | 3 | $46 |
| Jazz Pharmaceuticals Inc. | 3 | $44 |
| Sanofi | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Pfizer | 2 | $30 |
| Johnson & Johnson | 2 | $27 |
| Abbott | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Amgen | 1 | $19 |
| Novartis | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Intuitive Surgical | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$1,917 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Praluent PenAlirocumab | 14 | $7,958 |
| Levothyroxine Sodium | 12 | $192 |
| Famotidine | 11 | $59 |
| Atorvastatin Calcium | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Southlake
- Ronnie MitchellSouthlake$74K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.